Requests by FDA likely to delay Cyberkinetics nerve-growth stimulator

12/11/2007 | American City Business Journals

The FDA has asked Cyberkinetics Neurotechnology Systems to provide additional analyses and data on Andara, its implantable device that stimulates nerve growth in patients with acute spinal-cord injuries, before it grants a humanitarian device exemption for the product. The agency's additional requests are expected to delay the approval of the device until the first half of next year, the company said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ